Canada markets close in 4 hours 53 minutes

Sterling Capital Virginia Intermediate Tax-Free Fund C Shares (BVACX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
12.070.00 (0.00%)
As of 8:05AM EDT. Market open.
Full screen
Previous Close12.07
YTD Return-1.02%
Expense Ratio (net)1.56%
CategoryMuni Single State Interm
Last Cap Gain0.00
Morningstar Rating★★★★
Morningstar Risk RatingAverage
Sustainability RatingN/A
Net Assets82.82M
Beta (5Y Monthly)0.75
Yield0.66%
5y Average ReturnN/A
Holdings Turnover15.44%
Last Dividend0.01
Average for CategoryN/A
Inception DateFeb. 01, 2012
  • Philips integrates 3D ultrasound with innovative software for breakthrough in surveillance of abdominal aortic aneurysms
    GlobeNewswire

    Philips integrates 3D ultrasound with innovative software for breakthrough in surveillance of abdominal aortic aneurysms

    Philips AAA model in progress Philips AAA model results Philips AAA model Jan. 27, 2021 Philips Abdominal Aortic Aneurysm (AAA) Model helps increase diagnostic confidence and improved patient experience compared to current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has introduced the Philips Abdominal Aortic Aneurysm (AAA) Model, providing physicians a more patient-friendly solution compared to the current standard of care for managing AAA patients. Based on 3D ultrasound, Philips AAA Model delivers clinicians accurate diagnostic information without exposing patients to high doses of radiation and nephrotoxic contrast agents. An abdominal aortic aneurysm (AAA) is an aneurysm that forms in the lower part of the aorta. Typically, AAAs are identified incidentally during abdominal imaging exams but, in some cases, remain undetected until rupture. A ruptured AAA has an 80% mortality rate [1], emphasizing the importance of routine surveillance. Philips AAA Model integrates innovative software and leading Philips 3D ultrasound technologies into a single solution to help increase diagnostic confidence and an improved patient experience. The software automatically segments and quantifies the size of the aneurysm sac for surveillance of known native (untreated), and post-EVAR (treated) AAAs. The current standard of care for AAAs includes 2D ultrasound and computed tomography angiography (CTA). Each of these modalities has its drawbacks, including inter-operator variability with 2D ultrasound and patient exposure to high levels of radiation and nephrotoxic contrast agents with CTA. A recent clinical study showed that 3D ultrasound examination for native AAA surveillance has excellent inter-operator reproducibility, superior to that of 2D ultrasound, supporting the broader use of 3D ultrasound in standard AAA surveillance programs [2]. 3D ultrasound has been shown to estimate the diameter and volume of an AAA with acceptable reproducibility and an improved agreement (over 2D ultrasound) with CT [3]. Furthermore, 3D ultrasound has also been proven to correlate significantly better to 3D CT than 2D ultrasound for assessing the maximum diameter of the residual sac post-EVAR, with clinically acceptable reproducibility [4]. “Regular surveillance of abdominal aortic aneurysm patients is essential, but today’s standard of care has downsides,” said Bich Le, Senior Vice President, General Manager Ultrasound at Philips. “Philips Abdominal Aortic Aneurysm (AAA) Model seamlessly integrates leading Philips technologies including Philips Premium Ultrasound System (EPIQ Elite), Philips Array Transducer (X6-1 xMATRIX) and innovative software into a single solution, to help improve the experience and outcomes for clinicians and patients alike.” Launch of Philips Abdominal Aortic Aneurysm (AAA) Model at LINC 2021Philips will debut the AAA Model at the LINC (Leipzig Interventional Course) Summit, Europe’s premiere interventional course for vascular specialists, taking place virtually, Jan. 25-29, 2021. Visit Philips at LINC for more information on Philips AAA model, including live demos, and follow @PhilipsLiveFrom for updates throughout the virtual event. LINC attendees are also invited to attend a Symposium on Aortic Aneurysms, Friday, Jan. 29 at 12:30 PM CET, where clinicians will discuss the highest quality of care in complex EVAR procedure with advanced imaging techniques, from planning to follow-up. Participating in the Symposium is Prof. Henrik Sillesen who will address improving AAA measurement accuracy using innovative Ultrasound 3D volume moderation and xMATRIX. The Philips Abdominal Aortic Aneurysm (AAA) Model is CE marked for sale in Europe and is FDA cleared for sale in the U.S. [1] Age-specific incidence, risk factors, and outcome of acute abdominal aortic aneurysms in a definedpopulation. Howard DP, Banerjee A, Fairhead JF, et al. Br J Surg. 2015;102(8):907–915. doi:10.1002/bjs.9838[2] Clinical validation of three-dimensional ultrasound for abdominal aortic aneurysm. Ghulam, Qasam M. et al.,Journal of Vascular Surgery, Volume 71, Issue 1 [3] Three-dimensional ultrasound evaluation of small asymptomatic abdominal aortic aneurysms. Bredahl, K. etal. European Journal of Vascular and Endovascular Surgery, Volume 49, Issue 3, 289 – 296[4] Three-dimensional ultrasound improves the accuracy of diameter measurement of the residual sac in EVARpatients. K. Bredahl, M. Taudorf, A. Long, L. Lönn, L. Rouet, R. Ardon, H. Sillesen, J.P. Eiberg. European Journalof Vascular and Endovascular Surgery, Volume 46, Issue 5, 2013 For further information, please contact: Kathy O’ReillyPhilips Global Press OfficeTel.: +1 978-221-8919E-mail: kathy.oreilly@philips.com Twitter: @kathyoreilly About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachments Philips AAA model in progress Philips AAA model results Philips AAA model

  • Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon
    GlobeNewswire

    Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon

    Philips Stellarex low-dose drug-coated balloon January 25, 2021 Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the final, five-year results of two major randomized controlled trials (RCTs) that show no difference in all-cause mortality between patients treated with the Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care. Moreover, the studies showed no difference in mortality between the Stellarex DCB and PTA at every 12-month endpoint over the course of the study. Results from the two RCTs were presented at the virtual 2021 Leipzig Interventional Course (LINC). The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT together comprised approximately 600 patients in Europe and the U.S. After five years, the ILLUMENATE EU RCT showed 19.3% mortality among patients treated with the Stellarex DCB compared to 19.4% mortality for those treated with PTA. The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA (20.2%). Both studies had a high vital status follow-up compliance, with the status of over 90% of patients known. “The five-year final results show favourable overall safety of the Stellarex low-dose paclitaxel DCB, and are applicable within an extensive patient cohort,” said Marianne Brodmann, MD, Professor, vascular specialist at the Medical University of Graz, Austria, primary investigator for both trials and a paid consultant to Philips. “Every year, the Stellarex program has demonstrated low mortality rates with no difference in rates between the two patient cohorts.” “These study results build on the robust, consistent long-term data of the Stellarex program and confirm the safety and performance of our unique DCB,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “The Stellarex DCB, with its low drug dose and unique drug coating composition, continues to be an important treatment choice for healthcare providers treating patients with peripheral arterial disease.” Featuring Philips EnduraCoat technology, a unique coating consisting of a polyethylene glycol excipient with amorphous and crystalline paclitaxel particles dispersed in it, Stellarex .035” DCB is unlike any other drug-coated balloon for the treatment of peripheral artery disease. EnduraCoat technology provides efficient drug transfer and effective drug residency coupled with high coating durability and minimal particulate loss, thereby enabling a low therapeutic drug dose. Philips’ Image Guided Therapy business provides complete procedural solutions of systems, smart devices, disease-specific software and services for minimally invasive procedures, helping caregivers decide, guide, treat and confirm the right therapy for each patient during their procedure. For further information, please contact: Mark GrovesPhilips Global Press OfficeTel.: +31 631 639 916E-mail: mark.groves@philips.com Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622 698 001E-mail : fabienne.van.der.feer@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachment Philips Stellarex low-dose drug-coated balloon

  • Philips and Spanish healthcare group Vithas sign strategic agreement to incorporate Philips’ most advanced technologies into Vithas hospitals and clinics
    GlobeNewswire

    Philips and Spanish healthcare group Vithas sign strategic agreement to incorporate Philips’ most advanced technologies into Vithas hospitals and clinics

    Philips Ingenia Ambition X 1.5T MR scanner January 25, 2021 5-year alliance will provide Vithas Group with state-of-the-art diagnostic imaging, image viewing solutions, and minimally-invasive intervention technology to deliver faster and more accurate diagnosis and treatment to patientsVithas will become a ‘reference technology partner’ for Philips in Spain, giving it fast access to advances and innovations that Philips develops prior to their commercializationNew enterprise-wide network for diagnostic imaging will support unified working between more than 100 radiologists to facilitate workflow efficiency and research, as well as allowing patients to securely view their diagnostic reports and images on PCs and mobile devices Amsterdam, the Netherlands and Madrid, Spain – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Vithas Group, Spain’s second largest private healthcare group, today signed a 5-year innovation and collaboration agreement in the areas of precision diagnosis and image-guided intervention. The agreement will allow Vithas Group hospitals and medical centers to benefit from the latest innovations in diagnostic imaging technology, healthcare informatics, and equipment for minimally-invasive interventional procedures. Vithas Group hospitals and clinics offer healthcare and advanced medical care in thirteen provinces in seven autonomous regions of Spain. Under the terms of the agreement, Philips will deliver a technology management model that ensures Vithas Group’s current and future health technology needs in the relevant areas are met, together with the associated maintenance, updating, and equipment and system renewal needs. This management model will enable Vithas Group to achieve better results, provide optimal care at lower cost, and deliver a better experience for its patients and healthcare professionals. In addition, Vithas will become a ‘reference technology partner’ for Philips in Spain, which means that its hospitals and medical centers will be able to implement new advances and innovations developed by Philips, before standard commercialization of these solutions in Spain. "This new alliance with Philips integrates cutting-edge technology, healthcare excellence, innovation, and research, which are the fundamental pillars on which we support our commitment to always seek the best experience for our patients,” said Dr. Pedro Rico, CEO of Vithas Group. “Furthermore, our professionals will have the most advanced technological solutions at all times, which will reinforce the quality of care and facilitate their research work." “We are very excited about the trust placed in Philips and convinced that, through this collaboration agreement, Vithas will have all the technology and innovation necessary to continue achieving the best health results and the best experience for its patients and its healthcare professionals,” said Juan Sanabria, President of Philips Ibérica. “We are proud to become the technological partner and strategic ally of a group as important as Vithas.” The most advanced diagnostic imaging technologyThe agreement includes the replacement of Vithas Group’s existing MR imaging equipment with Philips’ latest innovative MR systems, which stand out for their image quality and patient comfort, and because they do not consume helium, also stand out for their sustainability. Philips will also install hybrid operating room solutions, including its latest ceiling mounted live-image guidance system for minimally-invasive interventional therapy, allowing Vithas hospitals to perform many types of procedure with maximum precision and safety. Four new hybrid operating rooms will be installed across four of the group’s hospitals. Next to this, Philips will replace the Vithas hospitals’ CT (Computed Tomography) equipment by high-end equipment, allowing them to perform more precise cardiac diagnoses thanks to the Philips equipment’s speed, coverage, and high image quality, while also minimizing radiation dose. The agreement also includes X-ray equipment, solutions for dose management, and a Corporate Network for Diagnostic Imaging. Benefits of the Corporate Network for Diagnostic ImagingThrough this network, and thanks to a solution for reviewing, post-processing and sharing information from advanced medical imaging studies, more than 100 radiologists will be able to work in a unified way with access to tools that speed up and improve the quality of results. Likewise, more than 5,000 referring physicians will have higher quality radiological reports directly available to them via a clinical viewer. The solution will also improve the patient experience, because they will be able to view their reports and images from any PC or mobile device via a secure web portal. Joint scientific researchThe innovation and collaboration agreement between Philips and Vithas Group will make it possible for the two organizations to collaborate in technological innovation projects in Vithas Group reference centers. These projects will involve joint scientific research in key healthcare areas, as well as the training of Vithas Group professionals in new technologies and clinical procedures. For further information, please contact: Joost MalthaPhilips Global Press OfficeTel.: +31 6 10 55 81 16E-mail: joost.maltha@philips.com César García RequenaBrand & Communications ManagerPhilips IbéricaTel : +34 670 264 471E-mail: cesar.garcia.requena@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. About Vithas Group Vithas' commitment: accredited healthcare quality, personal service and long-term vision. Vithas' strategic commitment is that all healthcare is endorsed by the standards of the most prestigious international quality accreditation, the Joint Commission International. Only 15 prestigious hospitals in Spain have such accreditation and recognition, and three of them are part of Vithas, in Madrid, Malaga and Granada. Every year Vithas treats more than 5,200,000 patients in its 19 hospitals and 21 Vithas Salud medical centers. The 40 centers are located throughout Spain and include hospitals in Alicante, Almería, Benalmádena, Castellón, Granada, Las Palmas de Gran Canaria, Lleida, Madrid, Málaga, Seville, Tenerife, Vigo, Valencia and Vitoria-Gasteiz. The 26 Vithas Salud centers are located in Alicante, Elche, El Ejido, Fuengirola, Granada, Las Palmas de Gran Canaria, Lleida, Madrid, Malaga, Nerja, Pontevedra, Rincón de la Victoria, Sanxenxo, Seville, Torre del Mar, Torremolinos, Vilagarcía de Arousa, and Vitoria-Gasteiz. Additionally, Vithas has more than 300 locations throughout Spain as part of the Vithas Lab laboratories network. Its PlazaSalud24 purchasing center, a benchmark in the sector, serves 39 hospitals, 35 medical centers and 20 dental clinics. Vithas has a stake in the leading hospital project in the Balearic Islands, the Juaneda Healthcare Network, which has 5 hospitals and a wide network of medical centers throughout the region. Vithas' commitment to proven quality healthcare and personalized service goes hand in hand with the strong support and long-term vision of Vithas' shareholders: Goodgrower, which controls 80% of the capital, and CriteriaCaixa, with the remaining 20%. With a growth model based on geographic diversification and sustainability, Vithas plans to continue consolidating its national presence both by opening new centers and through acquisitions and strategic agreements. www.vithas.es Attachment Philips Ingenia Ambition X 1.5T MR scanner